Ocugen Inc. (OCGN)
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders.
